N-[(3RS,4SR)-4-(3,4-dichloro-phenyl)-1-(1-ethanesulfonyl-piperidine-4-carbonyl)-pyrrolidin-3-yl]-4-methoxy-N-methyl-3-trifluoromethyl-benzamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: N-[(3RS,4SR)-4-(3,4-dichloro-phenyl)-1-(1-ethanesulfonyl-piperidine-4-carbonyl)-pyrrolidin-3-yl]-4-methoxy-N-methyl-3-trifluoromethyl-benzamide
• 英文别名: N-[(3R,4S)-4-(3,4-dichlorophenyl)-1-(1-ethylsulfonylpiperidine-4-carbonyl)pyrrolidin-3-yl]-4-methoxy-N-methyl-3-(trifluoromethyl)benzamide
• 化学式: C₂₈H₃₂Cl₂F₃N₃O₅S
• 分子量: 650.546
• InChiKey: UNDVLQKZTCWBNC-YKSBVNFPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  42
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  95.6
• 氢给体数：
  0
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  N-[(3RS,4SR)-4-(3,4-dichloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-4-methoxy-N-methyl-3-trifluoromethyl-benzamide 、 乙基磺酰氯 在 potassium carbonate 作用下， 以 丙酮 为溶剂， 反应 18.0h， 以76%的产率得到N-[(3RS,4SR)-4-(3,4-dichloro-phenyl)-1-(1-ethanesulfonyl-piperidine-4-carbonyl)-pyrrolidin-3-yl]-4-methoxy-N-methyl-3-trifluoromethyl-benzamide
  参考文献：
  名称：

  PYRROLIDINE DERIVATIVES AS NK2 RECEPTOR ANTAGONISTS

  摘要：

  本发明涉及式I的化合物，其中R1、R2、R3、Ar和n的定义如本文所述，并且其药用盐、拉克米混合物、对映体、光学异构体或其互变异构体。这些化合物可用于治疗抑郁症、焦虑症或精神分裂症。

  公开号：

  US20090312327A1

文献信息

• US8404679B2
  申请人：——

  公开号：US8404679B2

  公开（公告）日：2013-03-26
• [EN] PYRROLIDINE DERIVATIVES AS NK2 RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS DE PYRROLIDINE SERVANT D'ANTAGONISTES DES RÉCEPTEURS NK2
  申请人：HOFFMANN LA ROCHE

  公开号：WO2009153179A1

  公开（公告）日：2009-12-23

  The present invention relates to a compound of Formula (I) wherein R1 is hydrogen, halogen, cyano or lower alkyl; n is 1, 2 or 3; R2 is hydrogen or lower alkyl; R3 is an aryl- or a heteroaryl ring, wherein the rings are optionally substituted by one or two substituents R'; R' is selected from hydrogen, halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, lower alkoxy substituted by halogen,-S(O)2-lower alkyl, CN, -NR4R5, -C(O)-lower alkyl, heterocyclyl or heteroaryl; R4/R5 are independently from each other hydrogen, -(CO)CF3 or lower alkyl or is a non aromatic heterocyclic group (II) wherein X is N or CH; Y is -CH(R7)-; -N(R7')-, or O or can be SO2; R6 is hydrogen, lower alkyl or hydroxy; R7 is hydrogen, hydroxy, =0, lower alkyl, lower alkoxy, -S(O)2-lower alkyl, -C(O)-lower alkyl, -C(O)CH2O-lower alkyl, -CH2CN, -C(O)CH2CN, -C(O)-cycloalkyl wherein the cycloalkyl group is optionally substituted by cyano, lower alkyl, one or two halogen atoms, =0 or by amino, or is -C(O)O-lower alkyl, -NH-lower alkyl, -NRC(O)O-lower alkyl, -NRC(O)-lower alkyl or -CH2O-lower alkyl; and R7' is hydrogen, lower alkyl, -(CH2)q-S(O)2-lower alkyl, -(CH2)q-S(O)2-cycloalkyl, -C(O)-lower alkyl, -(CH2)q-cycloalkyl, -C(O)CH2-O-lower alkyl, -(CH2)qCN, -C(O)CN, -C(O)CH2CN, lower alkyl substituted by halogen, lower alkenyl substituted by halogen, -C(O)-cycloalkyl wherein the cycloalkyl group is optionally substituted by cyano, lower alkyl, one or two halogen atoms, =0 or by amino, or is -C(O)O-lower alkyl or -(CH2)qO-lower alkyl and q is O - 3; or R6 and R7 may form together with the carbon atoms to which they are attach a five or six- membered non aromatic ring or R6 and R7 may form together with the nitrogen and carbon atoms to which they are attach a five or six-membered non aromatic ring; p is 0, 1 or 2; Ar is aryl- or heteroaryl, wherein the rings are optionally substituted by one or two substituents R"; R' ' is selected from hydrogen, halogen, lower alkyl, lower alkyl substituted by halogen, lower alkoxy, lower alkoxy substituted by halogen, -O-CH2-cycloalkyl, -NR4R5, -CN, -CH(CH3)CN, -CH2O-lower alkyl or pyrrolyl; m is 0, 1 or 2 and o is 0; o is 0, 1 or 2 and m is 1 or pharmaceutically active salts, racemic mixtures, enantiomers, optical isomers or tautomeric forms thereof. The compounds may be used for the treatment of depression, anxiety or schizophrenia.
• PYRROLIDINE DERIVATIVES AS NK2 RECEPTOR ANTAGONISTS
  申请人：Bissantz Caterina

  公开号：US20090312327A1

  公开（公告）日：2009-12-17

  The present invention relates to compounds of formula I wherein R 1 , R 2 , R 3 , Ar and n are as defined herein and pharmaceutically active salts, racemic mixtures, enantiomers, optical isomers or tautomeric forms thereof. The compounds can be used for the treatment of depression, anxiety or schizophrenia.

  本发明涉及式I的化合物，其中R1、R2、R3、Ar和n的定义如本文所述，并且其药用盐、拉克米混合物、对映体、光学异构体或其互变异构体。这些化合物可用于治疗抑郁症、焦虑症或精神分裂症。